title: Antiviral agents and hepatitis C.
abstract: Hepatitis C is the leading cause of chronic hepatitis, cirrhosis, liver cancer and liver transplantation. In 70% to 80% of the people infected, the virus creates a chronic carrier state and the patient will be clinically asymptomatic or have mild symptoms. Two new direct-acting antiviral agents, boceprevir and telaprivir, both protease inhibitors, have been approved by the FDA for treatment of Hepatitis C genotype 1. The current hepatitis C post-exposure protocol is that no immediate post-exposure therapy is advised, but the dental healthcare worker should be tested periodically and offered antiviral therapy if a chronic carrier state exists.
authors.affiliation: Marcher@citytech.cuny.edu
authors.forename: Maureen
authors.initials: M
authors.lastname: Archer-Festa
authors.forename: Susan
authors.initials: S
authors.lastname: Nilsen-Kupsch
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D002353:Carrier State; D017742:Dental Care for Chronically Ill; D018937:Hepatitis C Antibodies / Q000097:blood; D019698:Hepatitis C, Chronic / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D019552:Infection Control, Dental / Q000379:methods; D009842:Oligopeptides / Q000627:therapeutic use; D015995:Prevalence; D011392:Proline / Q000031:analogs & derivatives / Q000627:therapeutic use; D011480:Protease Inhibitors / Q000627:therapeutic use
chemical_list: D000998:Antiviral Agents; D018937:Hepatitis C Antibodies; D009842:Oligopeptides; D011480:Protease Inhibitors; C486464:telaprevir; C512204:N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide; D011392:Proline